Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Launches RapidFire 365 High-Throughput Mass Spectrometry System

Published: Tuesday, June 11, 2013
Last Updated: Tuesday, June 11, 2013
Bookmark and Share
Product provides walkaway mass spectrometric analysis for researchers working on drug discovery, clinical research and forensic toxicology.

Agilent Technologies Inc. has launched the RapidFire 365 High-throughput Mass Spectrometry System.

The system offers increased plate capacity, full integration with Agilent’s BenchBot Robot automation technology and improved productivity for researchers working on drug discovery, clinical research and forensic toxicology.

Fully compatible with Agilent’s entire line of mass spectrometers, the RapidFire 365 high-throughput mass spectrometry system offers numerous advancements:

• The system runs unattended for up to 60 hours, facilitating more than 20,000 injections and enabling over-the-weekend runs.
• It analyzes multiple assays in a single, unattended run.
• It automates method development for novel analytes.
• It provides intuitive data review and visualization, using RapidFire Integrator 2.0 software.

The RapidFire 365 can also identify active compounds against challenging targets, confirm the activity of those compounds, and assess absorption, distribution, metabolism, elimination and physiochemical properties of those compounds.

“Agilent is excited to offer a single end-to-end platform for fast, cost-effective, automated, walkaway mass spectrometric analysis,” said Can (Jon) Ozbal, Ph.D., director of RapidFire operations.

Ozbal continued, “The RapidFire 365 brings us closer to our vision of creating a label-free MS-based workflow that rivals the simplicity of a plate reader while avoiding the pitfalls of optical assays.”

The new RapidFire system offers a strong application focus in HTS, including epigenetics and fragment-based drug discovery, as well as generating equivalent data to HPLC-MS in a fraction of the time and cost for a wide range of clinical research and forensic toxicology applications.

Agilent’s RapidFire solutions-front-end systems based on solid-phase extraction-enable detection of native compounds by mass spectrometry.

Requiring no labels or surrogates, RapidFire technology allows users to screen intractable or challenging targets that are not amenable to fluorescence or luminescence.

Sample throughput is 10 times faster than conventional MS screening methods.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Technologies Launches New Products for Analyzing Biotherapeutics
Expanded AdvanceBio portfolio enables scientists to speed research and lower costs.
Thursday, June 25, 2015
Agilent Announces New CEO Mike McMullen
McMullen elected as chief executive officer by Company’s board of directors.
Thursday, March 19, 2015
Agilent’s Microarray Scanner Approved for In Vitro Diagnostics in China
Regulators approve SureScan Dx as medical device.
Wednesday, January 28, 2015
Dako, Cell Signalling Tech Partner with Companion Diagnostics
Partnership for development of high-quality, cutting-edge companion diagnostic products for diagnosis and treatment of cancer.
Monday, January 12, 2015
Agilent Announces Global Distribution Agreement with Cartagenia for CNV Analysis
To assist cytogenetic labs in the clinical interpretation of microarray data.
Friday, May 30, 2014
Agilent Appoints Senior VP and President of Life Sciences and Diagnostics Group
Fred Strohmeier, has been named senior vice president, Agilent, and president of Agilent's Life Sciences and Diagnostics Group (LDG), effective immediately.
Wednesday, December 18, 2013
Dako Publishes Sixth Edition of Immunohistochemistry Guidebook
Reference book used by pathology laboratories worldwide.
Monday, December 16, 2013
Agilent Reports Fourth-Quarter Results
Agilent Technologies reported orders up 4 percent over one year ago to $1.83 billion with revenues of $1.72 billion, down 3 percent compared with one year ago.
Monday, November 18, 2013
Agilent Technologies to Separate into Two Public Companies
Life sciences, diagnostics and applied markets (LDA) that will retain the Agilent name, and the other company will be comprised of Agilent's electronic measurement (EM) products.
Monday, September 23, 2013
Agilent Technologies Announces Winner of Fifth Annual Early Career Professor Award
Assistant Professor at Northwestern Recognized for Cancer Diagnostics Research.
Friday, May 10, 2013
Dako to Offer New Antibody in U.S. to Diagnose Breast Cancer
Dako receives clearance to sell FLEX Monoclonal Rabbit Anti-Human Estrogen Receptor a, Clone EP1 in US.
Monday, April 08, 2013
Dako to Collaborate with Pfizer
Collaboration agreement in the field of companion diagnostics.
Monday, February 18, 2013
Dako Receives FDA Approval for Fast, Accurate, Nontoxic FISH Assay for Cancer Diagnostics
Dako, an Agilent Technologies Company, has introduced IQISH technology in the United States.
Monday, February 18, 2013
Agilent Technologies Microarrays Used in Groundbreaking Prenatal Research Study
Agilent Technologies Inc. announced its microarrays were used in a landmark prenatal research study published on Thursday in the New England Journal of Medicine.
Monday, December 10, 2012
Agilent Technologies Appoints Ron Nersesian President and COO
The company's board of directors has appointed Ron Nersesian Agilent president and chief operating officer, effective immediately.
Thursday, November 15, 2012
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Imaging Software Could Speed Breast Cancer Diagnosis
Technology could improve access to diagnostic services in developing countries.
Data Mining DNA For Polycystic Ovary Syndrome Genes
A new Northwestern Medicine genome-wide association study of PCOS – the first of its kind to focus on women of European ancestry – has provided important new insights into the underlying biology of the disorder.
Algorithm Interprets Breathing Difficulties to Aid in Medical Care
Researchers from North Carolina State University have developed an efficient algorithm that can interpret the wheezing of patients with breathing difficulties to give medical providers information about what’s happening in the lungs.
Researchers Develop qPCR Prognosis Test for NSCLC Patients
A nine-gene molecular prognostic index (MPI) for patients with early-stage non-small cell lung cancer (NSCLC) was able to provide accurate survival stratification and could potentially inform the use of adjuvant therapy in patients struggling with the disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!